1: Ricci A, Bronzetti E, Vega JA, Amenta F. Oral choline alfoscerate counteracts age-dependent loss of mossy fibres in the rat hippocampus. Mech Ageing Dev. 1992;66(1):81-91. PubMed PMID: 1340517.
2: Amenta F, Ferrante F, Vega JA, Zaccheo D. Long term choline alfoscerate treatment counters age-dependent microanatomical changes in rat brain. Prog Neuropsychopharmacol Biol Psychiatry. 1994 Sep;18(5):915-24. PubMed PMID: 7972861.
3: Kostenko EV, Petrova LV, Artemova IIu, Vdovichenko TV, Ganzhula PA, Ismailov AM, Lisenker LN, Petrov SV, Otcheskaia OV, Rotor LD, Khozova AA, Boĭko AN. [The use of cerepro (choline alfoscerate) in the treatment of outpatients with chronic progressive cerebrovascular disease]. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(3 Pt 1):24-30. Russian. PubMed PMID: 22677751.
4: Amenta F, Del Valle M, Vega JA, Zaccheo D. Age-related structural changes in the rat cerebellar cortex: effect of choline alfoscerate treatment. Mech Ageing Dev. 1991 Dec 2;61(2):173-86. PubMed PMID: 1824122.
5: Ciriaco E, Bronzetti E, Caporali MG, Germana' GP, Niglio T, Piccolo G, Ricci A, Scotti De Carolis A, Amenta F. Effect of choline alfoscerate treatment on changes in rat hippocampus mossy fibres induced by monolateral lesioning of the nucleus basalis magnocellularis. Arch Gerontol Geriatr. 1992 May-Jun;14(3):203-13. PubMed PMID: 15374385.
6: De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003 Jan;25(1):178-93. PubMed PMID: 12637119.
7: Bronzetti E, Felici L, Zaccheo D, Amenta F. Age-related anatomical changes in the rat hippocampus: retardation by choline alfoscerate treatment. Arch Gerontol Geriatr. 1991 Sep-Oct;13(2):167-78. PubMed PMID: 15374427.
8: Vega JA, Cavallotti C, del Valle ME, Mancini M, Amenta F. Nerve growth factor receptor immunoreactivity in the cerebellar cortex of aged rats: effect of choline alfoscerate treatment. Mech Ageing Dev. 1993 Jun;69(1-2):119-27. PubMed PMID: 8377526.
9: Kamilov KhM, Kasimova MS, Makhkamova DK. [Analysis of choline alfoscerate effectiveness in chronic ocular ischemic syndrome]. Vestn Oftalmol. 2016 Mar-Apr;132(2):73-6. Russian. PubMed PMID: 27213801.
10: Ilcol YO, Ozbek R, Hamurtekin E, Ulus IH. Choline status in newborns, infants, children, breast-feeding women, breast-fed infants and human breast milk. J Nutr Biochem. 2005 Aug;16(8):489-99. PubMed PMID: 16043031.
11: Holmes-McNary MQ, Cheng WL, Mar MH, Fussell S, Zeisel SH. Choline and choline esters in human and rat milk and in infant formulas. Am J Clin Nutr. 1996 Oct;64(4):572-6. PubMed PMID: 8839502.
12: Vinogradov OI, Daminov VD, Rybalko NV. [The use of choline alfoscerate (gliatiline) in patients with ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(1):43-5. Russian. PubMed PMID: 23528493.
13: Vaizova OE, Zautner NA, Alifirova VM, Vengerovskiĭ AI. [Influence of neuroprotectors with choline-positive action on the level of brain-injury markers during acute ischemic stroke]. Eksp Klin Farmakol. 2012;75(3):7-9. Russian. PubMed PMID: 22679745.
14: Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent. Curr Alzheimer Res. 2013 Dec;10(10):1070-9. Review. PubMed PMID: 24156263.
15: Tayebati SK, Amenta F. Choline-containing phospholipids: relevance to brain functional pathways. Clin Chem Lab Med. 2013 Mar 1;51(3):513-21. doi: 10.1515/cclm-2012-0559. Review. PubMed PMID: 23314552.